Span Divergent Ltd
₹ 38.5
0.00%
22 Jun
4:00 p.m.
About
Incorporated in 1972, Span Divergent Ltd deals in different businesses through various subsidiaries.[1]
Key Points
- Market Cap ₹ 28.0 Cr.
- Current Price ₹ 38.5
- High / Low ₹ 38.5 / 19.0
- Stock P/E
- Book Value ₹ 20.5
- Dividend Yield 0.00 %
- ROCE -30.0 %
- ROE -41.5 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 45.0 to 32.6 days.
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -15.9%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 75.47 | -0.00 | 2.87 | 14.57 | 24.14 | 9.38 | 7.40 | 13.09 | 12.52 | 12.33 | 8.96 | 17.23 | |
| 74.28 | 5.23 | 8.37 | 25.16 | 31.34 | 15.16 | 9.64 | 12.67 | 11.42 | 10.94 | 9.61 | 19.82 | |
| Operating Profit | 1.19 | -5.23 | -5.50 | -10.59 | -7.20 | -5.78 | -2.24 | 0.42 | 1.10 | 1.39 | -0.65 | -2.59 |
| OPM % | 1.58% | -191.64% | -72.68% | -29.83% | -61.62% | -30.27% | 3.21% | 8.79% | 11.27% | -7.25% | -15.03% | |
| 53.94 | 9.98 | 4.04 | 2.57 | -0.76 | 1.96 | 0.82 | -7.54 | -3.45 | 1.77 | 1.25 | 1.29 | |
| Interest | 4.39 | 0.03 | 0.20 | 1.70 | 1.89 | 1.99 | 1.58 | 1.08 | 1.00 | 0.72 | 0.60 | 0.43 |
| Depreciation | 5.96 | 0.18 | 0.82 | 2.60 | 3.62 | 3.45 | 3.11 | 2.17 | 2.17 | 1.64 | 1.09 | 1.17 |
| Profit before tax | 44.78 | 4.54 | -2.48 | -12.32 | -13.47 | -9.26 | -6.11 | -10.37 | -5.52 | 0.80 | -1.09 | -2.90 |
| Tax % | 12.93% | 27.97% | 5.24% | 1.46% | 4.31% | -7.02% | 0.82% | -2.12% | -1.81% | 2.50% | 17.43% | 1.38% |
| 38.99 | 3.28 | -2.61 | -12.50 | -14.05 | -8.61 | -6.16 | -10.15 | -5.42 | 0.79 | -1.28 | -2.95 | |
| EPS in Rs | 53.59 | 6.06 | -4.78 | -22.89 | -22.28 | -14.23 | -10.23 | -17.94 | -9.25 | 1.79 | -1.68 | -3.44 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 11% |
| TTM: | 92% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 9% |
| 3 Years: | -38% |
| TTM: | -95% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | 20% |
| 3 Years: | 36% |
| 1 Year: | 78% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -41% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.28 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 5.46 | 7.26 |
| Reserves | 54.41 | 44.71 | 43.11 | 30.61 | 19.87 | 12.12 | 6.56 | -3.24 | -8.30 | -7.35 | -8.27 | 7.60 |
| 0.34 | 0.19 | 13.12 | 23.18 | 22.30 | 19.19 | 17.99 | 13.19 | 11.15 | 9.11 | 8.36 | 7.14 | |
| 3.80 | 0.44 | 2.97 | 4.02 | 1.64 | 2.56 | 4.27 | 12.27 | 17.02 | 16.64 | 17.28 | 6.90 | |
| Total Liabilities | 65.83 | 50.80 | 64.66 | 63.27 | 49.27 | 39.33 | 34.28 | 27.68 | 25.33 | 23.86 | 22.83 | 28.90 |
| 2.20 | 2.15 | 8.15 | 25.91 | 22.47 | 20.19 | 17.72 | 15.36 | 13.12 | 10.75 | 9.64 | 9.33 | |
| CWIP | 0.09 | 0.06 | 10.95 | -0.00 | 0.06 | 0.13 | 0.02 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | 45.81 | 35.55 | 27.87 | 25.50 | 16.36 | 10.07 | 9.43 | 4.03 | 3.95 | 4.69 | 6.30 | 5.15 |
| 17.73 | 13.04 | 17.69 | 11.86 | 10.38 | 8.94 | 7.11 | 8.29 | 8.26 | 8.42 | 6.89 | 14.42 | |
| Total Assets | 65.83 | 50.80 | 64.66 | 63.27 | 49.27 | 39.33 | 34.28 | 27.68 | 25.33 | 23.86 | 22.83 | 28.90 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60.91 | -7.36 | -5.38 | -11.74 | -7.09 | -0.12 | -0.21 | 7.03 | 1.98 | 2.50 | 1.86 | 0.22 | |
| -12.13 | 13.39 | -5.55 | 0.81 | 10.05 | 5.89 | 1.99 | -2.05 | 0.53 | 0.12 | -1.05 | 1.55 | |
| -42.19 | -12.17 | 12.74 | 7.37 | -2.82 | -7.32 | -1.41 | -5.50 | -2.30 | -2.09 | -1.15 | 4.12 | |
| Net Cash Flow | 6.59 | -6.13 | 1.80 | -3.57 | 0.14 | -1.55 | 0.37 | -0.52 | 0.20 | 0.53 | -0.34 | 5.89 |
| Free Cash Flow | 47.54 | 3.91 | -21.44 | -15.13 | -6.93 | -1.46 | 1.79 | 8.12 | 1.85 | 2.12 | 1.91 | -0.19 |
| CFO/OP | 5,865% | 102% | 13% | 60% | 97% | -0% | 3% | 1,717% | 185% | 183% | -185% | -15% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 3.72 | 1.27 | 59.62 | 22.08 | 39.30 | 73.49 | 44.06 | 55.39 | 45.88 | 56.62 | 32.62 | |
| Inventory Days | 2.68 | 314.18 | 101.31 | 52.17 | 83.88 | 143.23 | 179.48 | 317.65 | 206.08 | 123.31 | 40.32 | |
| Days Payable | 1.17 | 78.54 | 39.95 | 12.44 | 79.35 | 298.01 | 213.76 | 526.78 | 480.26 | 426.66 | 136.20 | |
| Cash Conversion Cycle | 5.24 | 236.90 | 120.98 | 61.81 | 43.84 | -81.29 | 9.77 | -153.74 | -228.30 | -246.72 | -63.26 | |
| Working Capital Days | -7.01 | -705.84 | -228.22 | -185.98 | -310.52 | -400.02 | -428.58 | -599.98 | -608.63 | -930.83 | -111.43 | |
| ROCE % | -4.35% | -5.73% | -8.98% | -19.95% | -19.10% | -19.87% | -15.86% | -3.67% | -9.50% | 36.03% | -186.79% | -29.96% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees (Standalone) count ・Standalone data |
|
||||||||||
| Median Remuneration of Employees INR ・Standalone data |
|||||||||||
| Revenue by Segment - Cashew Processing INR Lacs |
|||||||||||
| Revenue by Segment - Tissue Culture INR Lacs |
|||||||||||
| Revenue by Segment - Trading (Life Sciences/Healthcare) INR Lacs |
|||||||||||
| Biological Asset Valuation (Tissue Culture) INR Lacs |
|||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Jun - Span Divergent Limited - Announcement under Regulation 30 (LODR) - Newspaper Publication
-
Span Divergent Limited - Intimation For Re-Appointment Of Internal Auditor Of The Company
30 May - M/s. Christie & Co. re-appointed as internal auditor for FY 2026-27.
- Span Divergent Limited -Intimation Of Book Closure 30 May
- Span Divergent Limited - Audited Standalone And Consolidated Results For March 31, 2026 30 May
-
Board Meeting Outcome for Span Divergent Limited - Outcome Of Board Meeting Held On May 30, 2026
30 May - FY26 audited standalone and consolidated results approved; no dividend; AGM on September 28, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
SDL operates across multiple business segments through dedicated subsidiaries in the Food, Agriculture, and Life Sciences verticals. It also provides management consulting and support services, offering financial, technical, and operational expertise to its group entities. The company actively oversees compliance, networking, and business development activities, while closely monitoring subsidiary performance and implementing strategic guidance and corrective measures as approved by the Board.